Human Coagulation Factor XIII Market Report: Trends, Forecast and Competitive Analysis to 2031

Human Coagulation Factor XIII Market Trends and Forecast

The future of the global human coagulation factor XIII market looks promising with opportunities in the surgery, disease treatment, and medical research markets. The global human coagulation factor XIII market is expected to grow with a CAGR of 7.8% from 2025 to 2031. The major drivers for this market are the rising healthcare expenditure in emerging market, the growing patient preference for recombinant & safer coagulation products, and the increasing awareness about coagulation factor XIII therapies.

• Lucintel forecasts that, within the type category, lyophilized powder is expected to witness higher growth over the forecast period.

• Within the application category, disease treatment is expected to witness the highest growth.

• In terms of region, APAC is expected to witness the highest growth over the forecast period. Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below.

Emerging Trends in the Human Coagulation Factor XIII Market

The human coagulation factor XIII market is experiencing rapid evolution driven by technological advancements, increasing clinical applications, and a growing global demand for innovative treatments for bleeding disorders. As research progresses, new formulations and delivery methods are emerging, alongside a focus on personalized medicine. These developments are transforming the landscape, making treatments more effective, accessible, and tailored to patient needs. The markets growth is also influenced by regulatory changes and increased awareness of rare bleeding disorders. Understanding these key trends is essential for stakeholders aiming to capitalize on opportunities and address challenges in this dynamic sector.

• Rising Adoption of Recombinant Factor XIII: Increased preference for recombinant over plasma-derived products due to safety and purity concerns. This trend enhances treatment efficacy and reduces infection risks, leading to broader acceptance among healthcare providers. The development of recombinant formulations also supports personalized dosing, improving patient outcomes. As regulatory approvals expand, market penetration is expected to grow, making recombinant Factor XIII the standard of care for many bleeding disorders.

• Advancements in Delivery Technologies: Introduction of novel delivery systems such as subcutaneous injections and long-acting formulations. These innovations improve patient compliance by reducing injection frequency and enhancing convenience. Long-acting products extend the duration of action, decreasing the treatment burden and improving quality of life. Such technological progress is attracting new patient segments and expanding market reach, especially among pediatric and elderly populations who require easier administration options.

• Growing Focus on Personalized Medicine: Tailoring treatments based on genetic and clinical profiles to optimize efficacy and minimize adverse effects. This approach involves developing biomarkers and diagnostic tools to identify suitable candidates for specific therapies. Personalized medicine enhances treatment success rates and reduces healthcare costs by avoiding ineffective therapies. The trend is fostering innovation in product development and encouraging collaborations between biotech firms and healthcare providers.

• Increasing R&D Investments and Regulatory Support: Significant investments in research and development aimed at discovering new formulations and indications. Regulatory agencies are providing clearer pathways for approval, facilitating faster market entry for innovative products. This supportive environment encourages startups and established companies to innovate, leading to a broader pipeline of advanced therapies. Enhanced R&D activity is expected to accelerate the availability of next-generation Factor XIII products, addressing unmet medical needs.

• Rising Global Demand and Market Expansion: Growing awareness and diagnosis of bleeding disorders worldwide, especially in emerging markets. Increased healthcare infrastructure and investment in rare disease management are driving market expansion. The rising prevalence of conditions like hemophilia and acquired Factor XIII deficiency fuels demand for effective therapies. Market players are expanding their geographic presence, establishing local manufacturing and distribution channels to meet regional needs, thus broadening the overall market scope. In summary, these emerging trends are collectively reshaping the human coagulation factor XIII market by fostering innovation, improving treatment options, and expanding access. The shift towards recombinant products, technological advancements, personalized approaches, supportive regulatory frameworks, and global market growth are creating a more dynamic, patient-centric landscape. These developments promise to enhance therapeutic outcomes and address unmet needs, positioning the market for sustained growth and evolution in the coming years.

Recent Development in the Human Coagulation Factor XIII Market

The human coagulation factor XIII market has experienced significant advancements driven by increasing prevalence of bleeding disorders, technological innovations, and expanding therapeutic applications. These developments are shaping the landscape of treatment options, improving patient outcomes, and expanding market opportunities. As research progresses, new formulations and delivery methods are emerging, alongside regulatory approvals and strategic collaborations. These factors collectively influence market growth, competitive dynamics, and prospects. Understanding these key developments is essential for stakeholders aiming to capitalize on emerging trends and address unmet medical needs within this specialized sector.

• Introduction of recombinant Factor XIII products: These products offer enhanced safety and reduced risk of pathogen transmission, leading to increased adoption among healthcare providers and patients, thereby expanding the market and improving treatment efficacy.

• Regulatory approvals for new therapies: Recent approvals by agencies such as the FDA and EMA have facilitated market entry for innovative Factor XIII therapies, accelerating availability and encouraging further research and development in this field.

• Advances in delivery methods: Development of novel delivery systems, including subcutaneous injections and long-acting formulations, has improved patient compliance and convenience, positively impacting market growth and treatment adherence.

• Growing prevalence of bleeding disorders: Rising incidences of conditions like congenital Factor XIII deficiency and acquired bleeding disorders have increased demand for effective therapies, driving market expansion and research investments.

• Strategic collaborations and mergers: Partnerships between pharmaceutical companies and biotech firms have fostered innovation, expanded product pipelines, and enhanced manufacturing capabilities, strengthening market competitiveness and accelerating product development. In summary, these recent developments are significantly impacting the human coagulation factor XIII market by enhancing product safety, expanding therapeutic options, and improving patient outcomes. The market is poised for continued growth driven by technological innovations, regulatory support, and increasing disease prevalence, making it a dynamic and promising sector for stakeholders.

Strategic Growth Opportunities in the Human Coagulation Factor XIII Market

The human coagulation factor XIII market is experiencing rapid growth driven by increasing prevalence of bleeding disorders, advancements in biopharmaceuticals, and expanding applications in surgical and trauma care. As the demand for effective hemostatic agents rises, key applications are emerging as significant growth drivers. These opportunities are shaping the future landscape of the market, offering innovative solutions for patient care and expanding market reach. Companies are investing in research and development to capitalize on these trends, which are expected to enhance product portfolios and improve treatment outcomes across various medical fields.

• Hemophilia Treatment: The increasing incidence of hemophilia and other bleeding disorders is driving demand for Factor XIII products. These therapies are crucial for preventing bleeding episodes and improving quality of life, leading to a surge in market growth and innovation in treatment options.

• Surgical Hemostasis: The rising number of surgeries, especially complex and minimally invasive procedures, necessitates effective hemostatic agents. Factor XIIIs role in promoting clot stability enhances surgical outcomes, creating significant opportunities for market expansion in perioperative care.

• Trauma Care: Growing cases of traumatic injuries require rapid hemostasis solutions. Factor XIIIs ability to facilitate clot formation and tissue repair positions it as a vital component in trauma management, opening avenues for new product development and market penetration.

• Neonatal and Pediatric Care: The need for safe and effective bleeding management in neonates and children is increasing. Factor XIII therapies tailored for pediatric use are gaining attention, offering potential for specialized formulations and expanding market share in pediatric healthcare.

• Veterinary Applications: The use of Factor XIII in veterinary medicine is emerging as a niche but promising segment. Its application in managing bleeding disorders in animals presents new growth opportunities, diversifying the market and fostering innovation in veterinary therapeutics. In summary, these key growth opportunities are significantly impacting the human coagulation factor XIII market by broadening its application scope, enhancing treatment efficacy, and fostering innovation. This expansion is expected to lead to increased market size, improved patient outcomes, and a competitive landscape driven by technological advancements and unmet medical needs.

Human Coagulation Factor XIII Market Driver and Challenges

The human coagulation factor XIII market is influenced by a variety of technological, economic, and regulatory factors that shape its growth and development. Advances in biotechnology and medical research have led to improved formulations and delivery methods, expanding treatment options. Economic factors such as increasing healthcare expenditure and rising prevalence of bleeding disorders drive demand. Regulatory frameworks ensure safety and efficacy, fostering market confidence. However, challenges like high treatment costs, stringent approval processes, and limited awareness pose obstacles. Understanding these drivers and challenges is essential for stakeholders aiming to capitalize on market opportunities and address potential barriers effectively. The factors responsible for driving the human coagulation factor XIII market include:

• Technological Advancements: The development of recombinant factor XIII products has revolutionized treatment by reducing reliance on plasma-derived products, minimizing infection risks, and improving safety profiles. Innovations in drug delivery systems, such as subcutaneous injections and long-acting formulations, enhance patient compliance and convenience. These technological improvements have expanded the market by offering more effective and safer options, encouraging broader adoption among healthcare providers and patients. Continuous R&D efforts are expected to further refine these therapies, supporting sustained market growth.

• Rising Prevalence of Bleeding Disorders: An increasing incidence of congenital and acquired bleeding disorders, such as hemophilia and factor XIII deficiency, significantly propels market demand. Factors like aging populations, genetic predispositions, and improved diagnostic techniques contribute to higher detection rates. As awareness grows, more patients seek treatment, expanding the market size. The growing burden of these disorders underscores the need for effective therapies, thereby fueling innovation and investment in the development of human coagulation factor XIII products.

• Increasing Healthcare Expenditure: The global rise in healthcare spending, especially in emerging economies, facilitates greater access to advanced therapies, including coagulation factors. Governments and private insurers are investing more in healthcare infrastructure and treatment options, which enhances patient access to diagnosis and management of bleeding disorders. This economic support encourages pharmaceutical companies to invest in research and expand distribution networks, ultimately boosting market growth. Additionally, reimbursement policies and insurance coverage play crucial roles in making these therapies more affordable and accessible.

• Regulatory Approvals and Support: Stringent regulatory frameworks ensure the safety, efficacy, and quality of coagulation factor products, fostering trust among healthcare providers and patients. Recent approvals of novel recombinant factor XIII therapies by agencies like the FDA and EMA have accelerated market expansion. Regulatory support also encourages innovation by providing clear pathways for new product development. Moreover, government initiatives and collaborations with research institutions promote clinical trials and facilitate faster approval processes, thereby positively impacting market growth.

• Growing Awareness and Diagnosis: Increased awareness about bleeding disorders and the importance of early diagnosis have led to higher detection rates. Educational campaigns, improved screening programs, and better diagnostic tools enable timely intervention, which is critical for effective management. As more patients are diagnosed, the demand for coagulation factor XIII therapies rises. Enhanced awareness also encourages healthcare providers to adopt advanced treatment protocols, further expanding the market and improving patient outcomes. The challenges facing this Market include:

• High Treatment Costs: The cost of human coagulation factor XIII therapies remains a significant barrier, especially in low- and middle-income countries. Recombinant products and advanced formulations are expensive to develop and manufacture, leading to high prices for end-users. This financial burden limits patient access and adherence, impacting overall market growth. Payers and healthcare systems often face difficulties in covering these costs, which can restrict widespread adoption and place pressure on manufacturers to find cost-effective solutions without compromising quality.

• Stringent Regulatory Processes: While regulatory oversight ensures product safety, it also presents hurdles for market entry. Lengthy approval timelines, complex documentation requirements, and the need for extensive clinical trials can delay the launch of new therapies. Smaller companies may struggle to meet these regulatory demands, limiting innovation and competition. Navigating diverse regulatory landscapes across regions adds further complexity, potentially hindering rapid market expansion and the availability of novel treatments.

• Limited Awareness and Diagnosis: Despite advancements, awareness about bleeding disorders and the importance of early diagnosis remains inadequate in some regions. Limited access to specialized healthcare providers and diagnostic facilities hampers timely detection and treatment initiation. This results in underdiagnosis and undertreatment, constraining market growth. Additionally, cultural barriers and lack of education can prevent patients from seeking care, thereby reducing demand for coagulation factor XIII products and slowing overall market development. In summary, the human coagulation factor XIII market is driven by technological innovations, increasing disease prevalence, economic support, regulatory facilitation, and heightened awareness. However, high costs, regulatory challenges, and limited diagnosis hinder its growth. Addressing these barriers through cost reduction strategies, streamlined approval processes, and awareness campaigns will be crucial for sustainable market expansion. Overall, the market holds significant potential, provided these challenges are effectively managed to improve patient access and treatment outcomes.

List of Human Coagulation Factor XIII Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies human coagulation factor XIII companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the human coagulation factor XIII companies profiled in this report include-

• CSL Behring

• Merck KGaA

• Invitrogen (Thermo Fisher Scientific Inc.)

• ZEDIRA GmbH

• Sino Biological, Inc.

• Cell Sciences, Inc.

• Enzyme Research Laboratories Inc.

Human Coagulation Factor XIII Market by Segment

The study includes a forecast for the global human coagulation factor XIII market by type, application, and region.

Human Coagulation Factor XIII Market by Type [Value from 2019 to 2031]:

• Lyophilized Powder

• Liquid

Human Coagulation Factor XIII Market by Application [Value from 2019 to 2031]:

• Surgery

• Disease Treatment

• Medical Research

• Others

Human Coagulation Factor XIII Market by Region [Value from 2019 to 2031]:

• North America

• Europe

• Asia Pacific

• The Rest of the World

Country Wise Outlook for the Human Coagulation Factor XIII Market

The human coagulation factor XIII market has experienced significant shifts driven by technological advancements, increasing clinical applications, and evolving healthcare policies worldwide. As the demand for innovative treatments for bleeding disorders grows, key markets are investing in research and development to improve product efficacy and safety. Regulatory approvals and strategic collaborations are also shaping the competitive landscape. These developments reflect a broader trend toward personalized medicine and enhanced patient outcomes, influencing market dynamics across major regions. The following summaries highlight recent key advancements and strategic movements in the United States, China, Germany, India, and Japan.

• United States: The US market has seen increased approval of novel Factor XIII products, with major pharmaceutical companies investing heavily in R&D. There is a rising adoption of recombinant therapies, and clinical trials are exploring new indications for Factor XIII in wound healing and other bleeding disorders. Regulatory agencies have streamlined approval processes, accelerating market entry for innovative solutions. Additionally, growing awareness and diagnosis of rare bleeding disorders are fueling demand, supported by expanding healthcare infrastructure and reimbursement policies.

• China: China’s market is rapidly expanding due to government initiatives promoting biotechnology and innovative therapies. Local companies are increasing their R&D efforts, leading to the development of cost-effective recombinant Factor XIII products. The government’s focus on improving healthcare access and increasing awareness of bleeding disorders has boosted market growth. Strategic collaborations with international firms are facilitating technology transfer and product localization. Moreover, regulatory reforms are simplifying approval processes, encouraging more domestic production and market penetration.

• Germany: Germany remains a key European hub for coagulation factor research and production, with a strong emphasis on recombinant and plasma-derived products. Recent advancements include the development of more refined formulations with improved safety profiles. The country’s robust healthcare system and high awareness of bleeding disorders support steady market growth. Regulatory bodies have approved several innovative therapies, and ongoing clinical trials aim to expand treatment options. Germany’s focus on personalized medicine and precision therapies is driving innovation in Factor XIII applications, strengthening its position in the European market.

• India: India’s market is witnessing rapid growth driven by the increasing prevalence of bleeding disorders and rising healthcare expenditure. Local manufacturers are expanding their portfolios with affordable recombinant Factor XIII products to meet domestic demand. Government initiatives to promote biotech innovation and improve healthcare infrastructure are facilitating market expansion. Additionally, partnerships with global firms are enabling technology transfer and product development. The regulatory environment is gradually becoming more conducive to faster approvals, and increasing awareness campaigns are encouraging early diagnosis and treatment, further propelling market growth.

• Japan: Japan’s market is characterized by high adoption of advanced biotechnologies and a focus on innovative therapies. Recent developments include the approval of new recombinant Factor XIII formulations with enhanced efficacy and safety. The country’s aging population and increasing prevalence of bleeding disorders are driving demand. Japan’s strong healthcare infrastructure and emphasis on research and development support ongoing clinical trials and product innovation. Regulatory agencies are actively approving novel therapies, and collaborations between academia and industry are fostering new treatment approaches. These factors collectively contribute to Japan’s leadership position in the global human coagulation factor XIII market.

Features of the Global Human Coagulation Factor XIII Market

Market Size Estimates: Human coagulation factor XIII market size estimation in terms of value ($B). Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions. Segmentation Analysis: Human coagulation factor XIII market size by type, application, and region in terms of value ($B). Regional Analysis: Human coagulation factor XIII market breakdown by North America, Europe, Asia Pacific, and Rest of the World. Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the human coagulation factor XIII market. Strategic Analysis: This includes M&A, new product development, and competitive landscape of the human coagulation factor XIII market. Analysis of competitive intensity of the industry based on Porter’s Five Forces model.

FAQ

Q1. What is the growth forecast for human coagulation factor XIII market? Answer: The global human coagulation factor XIII market is expected to grow with a CAGR of 7.8% from 2025 to 2031. Q2. What are the major drivers influencing the growth of the human coagulation factor XIII market? Answer: The major drivers for this market are the rising healthcare expenditure in emerging market, the growing patient preference for recombinant & safer coagulation products, and the increasing awareness about coagulation factor XIII therapies. Q3. What are the major segments for human coagulation factor XIII market? Answer: The future of the human coagulation factor XIII market looks promising with opportunities in the surgery, disease treatment, and medical research markets. Q4. Who are the key human coagulation factor XIII market companies? Answer: Some of the key human coagulation factor XIII companies are as follows:

• CSL Behring

• Merck KGaA

• Invitrogen (Thermo Fisher Scientific Inc.)

• ZEDIRA GmbH

• Sino Biological, Inc.

• Cell Sciences, Inc.

• Enzyme Research Laboratories Inc. Q5. Which human coagulation factor XIII market segment will be the largest in future? Answer: Lucintel forecasts that, within the type category, lyophilized powder is expected to witness higher growth over the forecast period. Q6. In human coagulation factor XIII market, which region is expected to be the largest in next 5 years? Answer: In terms of region, APAC is expected to witness the highest growth over the forecast period. Q7. Do we receive customization in this report? Answer: Yes, Lucintel provides 10% customization without any additional cost.